Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 11/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 3/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316970 | 0.81 | EPHX1 (0.73) | EPHX1 | |
| SCHEMBL28832897 | 0.74 | FOLH1 (0.48) | FOLH1ANPEPENPEPMEP1B | |
| SCHEMBL11706976 | 0.73 | EPHX1 (0.69) | EPHX1 | |
| SCHEMBL765921 | 0.72 | FOLH1 (0.61) | FOLH1ANPEPENPEPMEP1B | |
| SCHEMBL6193643 | 0.71 | FOLH1 (0.51) | FOLH1ANPEPENPEPMEP1B | |
| SCHEMBL14508907 | 0.71 | FOLH1 (0.75) | FOLH1ANPEPENPEP | |
| SCHEMBL13543995 | 0.71 | FOLH1 (0.56) | FOLH1ANPEPENPEPMEP1B | |
| SCHEMBL10371950 | 0.71 | FOLH1 (0.56) | FOLH1ANPEPENPEPMEP1B | |
| SCHEMBL9921264 | 0.71 | FOLH1 (0.56) | FOLH1ANPEPENPEPMEP1B | |
| SCHEMBL20015998 | 0.71 | EPHX1 (0.49) | EPHX1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013178682-A2 | MULTICOMPONENT PROCESS FOR THE PREPARATION OF BICYCLIC COMPOUNDS | CHEMO IBÉRICA, S.A. (ES) | 2013-12-05 | — | — | WO | disclosed |
| US-20090182057-A1 | DEUTERATED AMINOGLYCIDAL COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182057-A1 | DEUTERATED AMINOGLYCIDAL COMPOUNDS | ADRB2, GLRB, ADRB1 | EPHX1 3582/4885FOLH1 4445/4885ANPEP 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.